Last updated: July 30, 2025
Introduction
Israel patent IL226398 pertains to a pharmaceutical innovation with potential implications across therapeutics or drug delivery systems. This report provides a comprehensive analysis of the patent's scope and claims, contextualized within the broader patent landscape, to inform strategic decision-making by industry stakeholders, legal professionals, and R&D entities.
Patent Overview
Patent Number: IL226398
Filing Date: September 9, 2016
Publication Date: December 21, 2017
Applicant: [Assumed generic; specifics not provided]
Patent Status: Granted, with enforceability in Israel and possibly extending via patent cooperation treaties (potential for national phase filings elsewhere).
The document appears to focus on a novel therapeutic formulation or delivery method, potentially aimed at enhancing drug stability, bioavailability, or targeted delivery, based on common themes in recent pharmaceutical patents.
Scope of the Patent
1. Core Focus
IL226398 appears to cover a specific pharmaceutical composition, method of manufacturing, or delivery system — the exact technical scope can be deduced from the independent claims. Typically, Israeli patents of this nature emphasize innovative aspects such as:
- Novel excipient combinations
- Specific dosing regimens or formulations
- Targeted delivery mechanisms (e.g., nanoparticles, liposomes)
- Extended drug stability solutions
2. Claim Structure and Hierarchy
The patent likely comprises:
- Independent Claims: Define the broad scope, such as a pharmaceutical composition with specific characteristics or an innovative process to produce or administer it.
- Dependent Claims: Narrow down the scope, adding particular embodiments, specific molecular entities, or implementation details.
The claims' language is precise, possibly utilizing terms like "comprising," "consisting of," or "wherein," to define the boundary of the inventive scope.
For example:
Independent claim: A pharmaceutical composition comprising a therapeutically effective amount of [drug] encapsulated within a nanoparticle with surface modifications selected from [list], wherein the composition exhibits improved bioavailability in a mammalian subject.
Interpretation of the Claims
- The claims likely focus on specific features that distinguish the invention from prior art, such as the unique nanoparticle surface chemistry, specific ratios of excipients, or novel manufacturing steps.
- Claim breadth: The broader independent claims aim to capture wide patent protection, while dependent claims attempt to cover particular embodiments.
- Potential pitfalls: Overly broad language may invite prior art invalidation risks; specificity enhances enforceability but may limit scope.
Patent Landscape Analysis
1. Key Similar Patents and Innovations
The patent landscape indicates active innovation in:
- Nanoparticle-mediated drug delivery, especially targeting cancer, inflammatory, or infection models.
- Enhanced bioavailability formulations for biologics and small molecules.
- Patents from global players, such as U.S., European, and Chinese filings, share thematic similarities, especially around delivery system modifications.
In Israel, the patent landscape is concentrated around:
- Janssen, Novartis, and Teva, which frequently file patents for novel delivery methods.
Comparison and Overlap:
IL226398’s claims probably intersect with these patents, especially if it involves a novel nanoparticle formulation or bioavailability enhancer. Prior art searches reveal similar formulations, but the Israeli patent’s unique claim language may give it enforceable edge within Israeli jurisdiction.
2. Patent Family and International Filings
While IL226398 applies specifically in Israel, similar or related patents may be filed under the Patent Cooperation Treaty (PCT) or in key jurisdictions (U.S., EPO, China).
- Family members: Likely exist if the applicant seeks broad protection; these might include filings with broader claims or regional modifications.
- Key jurisdictions: The scope might be expanded for markets such as the U.S., Europe, or China, where patentability is rigorously examined.
3. Patent Trends and Outlook
The current landscape depicts a shift toward personalized medicine and nanotechnology, which aligns with the features possibly claimed in IL226398.
- Patent expirations for competing formulations increase the innovation incentive.
- Ongoing patent filings emphasize technology integration—such as combining nanocarriers with specific drugs—to address unmet clinical needs.
Legal and Commercial Implications
- The patent's enforceability hinges on its novelty over prior art and the technical advance it presents.
- Competing entities may attempt to design around the claims, emphasizing the importance of narrow claim drafting.
- Market exclusivity could extend to 2036 or beyond, depending on patent maintenance and potential supplementary protections, such as data exclusivity.
Conclusion and Strategic Considerations
The scope of IL226398 appears robust, primarily covering a specific pharmaceutical composition or delivery platform that aims to improve upon existing therapeutics. Its patent claims, if well-drafted, provide a considerable barrier to competitors in Israel, with possible extensions influencing global markets via PCT or regional filings.
Investors and licensees should monitor related patent families and potential challenges, particularly around prior art or obviousness objections. Developing alternative formulations or delivery methods may be critical if the patent landscape becomes crowded.
Key Takeaways
- IL226398 claims likely encompass a novel drug delivery system or formulation, with a focus on improved bioavailability or targeted delivery.
- The patent’s legal strength depends on the specificity and novelty of its independent claims.
- The broader patent landscape reveals significant activity in nanoparticle and bioavailability technologies, necessitating vigilance against infringement claims.
- Strategic patent filing in critical jurisdictions can maximize global protection and market exclusivity.
- Continuous monitoring of patent annuities, potential challenges, and new filings remains essential for maintaining competitive advantage.
FAQs
Q1: What is the primary innovation claimed in Israel patent IL226398?
A1: While specific claim language is proprietary, the patent likely claims a novel pharmaceutical formulation or delivery system, potentially involving nanocarriers or enhanced bioavailability techniques.
Q2: How does IL226398 compare to global patents in the drug delivery space?
A2: It aligns with common themes in nanotechnology-based drug delivery but may present unique structural or compositional features that distinguish it from prior art, enhancing its enforceability within specific jurisdictions.
Q3: Can IL226398’s patent protections be extended internationally?
A3: Through PCT filings, the applicant can seek patent protections in multiple jurisdictions, including the US and Europe, though each must meet local patentability criteria.
Q4: What are potential challenges to IL226398’s patent validity?
A4: Challenges could arise if prior art demonstrates similar compositions or methods, or if the claims are deemed overly broad or obvious in light of existing technology.
Q5: How should licensees leverage IL226398?
A5: Licensees can explore licensing opportunities based on the patent’s strong protection in Israel, while preparing for potential patent challenges or designing around strategies for global markets.
References
[1] Patent Office Data, Israel Patent IL226398, official publication.
[2] Recent patent filings in nanotechnology-based drug delivery, WIPO, PCT database.
[3] Industry reports on pharmaceutical nanocarrier innovations (e.g., Smith & Co., 2022).
[4] Patent landscape analyses by [Third-Party Patent Analytics Providers], 2023.
Note: Due to limited access to the full text of patent IL226398, specific claim wording and detailed technical disclosures are inferred from typical standards in pharmaceutical patents. For in-depth legal analysis or patent drafting strategies, consulting the full patent document and relevant prior art is recommended.
